Overview

Warfarin and Antiplatelet Vascular Evaluation

Status:
Unknown status
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether the addition of warfarin (a blood-thinning medication) to an antiplatelet therapy like aspirin is better than antiplatelet therapy alone (i.e. usual treatment) for the prevention of leg surgery, heart attacks, stroke and death in people with peripheral vascular disease.
Phase:
Phase 3
Details
Lead Sponsor:
Anand, Sonia, M.D.
Collaborators:
Canadian Institutes of Health Research (CIHR)
Heart and Stroke Foundation of Ontario
Treatments:
Warfarin